Introduction: Hyperammonemia is a potential adverse effect of valproic acid (VPA) therapy, which is often asymptomatic but can lead to severe, life-threatening encephalopathy. Carnitine deficiency due to VPA is the proposed mechanism for hyperammonemia and the development of VPA-induced hyperammonemic encephalopathy (VHE). Levocarnitine, the active form of carnitine, has been suggested for treatment and prevention of VHE. Methods: Data was collected by chart review of 3 patients who received oral levocarnitine supplementation in the psychiatric setting for VPA-induced hyperammonemia. Review of the literature was performed through June 2017 using the following PubMed search terms: valproate, valproic acid, hyperammonemia, altered mental status, encephalopathy, and levocarnitine. Articles were included if they described use of levocarnitine in VPA-treated patients with psychiatric disorders. Results: One patient developed encephalopathy with resolution of symptoms after VPA discontinuation. Valproic acid was restarted with the addition of levocarnitine to prevent VHE reoccurrence. In the other 2 cases, levocarnitine was started prophylactically in patients who developed hyperammonemia without emergence of any clinical symptoms. Ammonia levels were reduced to normal in all cases, and no symptoms consistent with encephalopathy were reported. The literature search identified 6 additional cases with 5 of 6 reports supporting use of levocarnitine for decreased ammonia levels as well as an observational trial. Discussion: This literature review and case series illustrates successful use of levocarnitine supplementation for reduction of ammonia levels in the setting of VPA-induced hyperammonemia among patients with psychiatric disorders. However, clinical significance of ammonia reduction in asymptomatic patients is difficult to determine.
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Background
Valproic acid (VPA) is a branched carboxylic acid used to treat various psychiatric illnesses as well as seizure disorders and migraines. In the psychiatric population, VPA is primarily utilized for its mood stabilizing properties and with a limited number of medications effective for this purpose, tolerability issues are an important concern. One potentially harmful adverse effect that may occur as a result of VPA treatment is hyperammonemia. Although many patients with hyperammonemia remain asymptomatic, elevated ammonia levels can lead to life-threatening VPA-induced hyperammonemic encephalopathy (VHE). Clinical symptoms of VHE have been characterized by lethargy, nausea/vomiting, cognitive slowing, focal neurological deficits, and decreased levels of consciousness, ranging from drowsiness to coma. [1] [2] [3] Structurally, VPA is similar to short-chain fatty acids and is a substrate for fatty acid mitochondrial b-oxidation and cytoplasmic x-oxidation pathways. Carnitine is an essential cofactor in the metabolism of fatty acids and mitochondrial energy production. During VPA therapy, carnitine combines with VPA to form valproylcarnitine. As a minor route of elimination, valproylcarnitine is excreted in the urine. Valproylcarnitine also inhibits the membrane transporter responsible for transferring extracellular carnitine into the cell and mitochondria. Additionally, VPA metabolites trap mitochondrial coenzyme A so that carnitine cannot be restored through the action of carnitine palmitoyl transferase II. Reduced carnitine from these mechanisms results in decreased b-oxidation of VPA and shifts the metabolism toward predominately xoxidation, producing a toxic metabolite, 2-propyl-4-pentenoic acid (4-en-VPA). This metabolite reduces ammonia elimination through inhibition of carbamoylphosphate synthase I, the first enzyme in the urea cycle, thus, increasing ammonia levels. 4 In 1989, levocarnitine (L-carnitine, active isoform of carnitine) received Food and Drug Administration orphan drug designation for the prevention and treatment of secondary carnitine deficiency in VPA toxicity. 5 Review articles 4,6,7 have described levocarnitine supplementation for VHE in the setting of acute valproic acid overdose. Levocarnitine has also been suggested for treatment and prevention of VHE in patients treated with usual VPA doses. However, the majority of evidence supporting this use comes from pediatric neurology literature. 7 The present article discusses 3 cases of levocarnitine supplementation for hyperammonemia in the context of VPA treatment of psychiatric disorders and provides a review of the current literature.
Cases Case 1
A 65-year-old male with bipolar I disorder was admitted to the inpatient psychiatry unit for an acute manic episode.
His outpatient medication regimen, past medical history, and admission labs are described in Table 1. On admission, outpatient psychiatric medications were discontinued and VPA solution (500 mg every morning, 1000 mg every evening) and risperidone tablets (1 mg twice daily) were initiated. Valproate and risperidone were titrated to doses of 3000 mg/d and 6 mg/d, respectively, over the course of 5 days. On day 7, the patient became somnolent, which progressed to garbled speech and altered mental status. Laboratory testing revealed a VPA level of 68 lg/mL (lab reference range: 50 to 100 lg/mL) and an ammonia level of 56 lmol/L (lab reference range: 16 to 53 lmol/L). Valproate was discontinued with resolution of symptoms. Following VPA discontinuation, staff noted reemergence of mania symptoms, including agitation and hypersexual behaviors. On day 11 of admission, lithium 900 mg/d was initiated and VPA solution was restarted at a lower dose of 1000 mg/d, which was eventually increased to 1500 mg/d divided twice daily. At the time of VPA dose increase, levocarnitine 990 mg daily was initiated to prevent VHE and was increased 3 days later to 990 mg twice daily. Blood levels were rechecked 2 weeks later, and ammonia was found to be 23 lmol/L and the VPA level was 50 lg/mL. No symptoms of encephalopathy were reported during the admission after levocarnitine was started.
Valproate was continued as an outpatient but for reasons unknown, levocarnitine was not renewed. Approximately 3 months after inpatient discharge, the patient was admitted to the hospital for encephalopathy with an elevated ammonia level of 66 lmol/L and a low VPA level of 19 lg/mL as it was held for somnolence. Valproate was discontinued and not restarted.
Case 2
A 64-year-old male with schizoaffective disorder, bipolar type, was admitted to the inpatient psychiatric unit for disorganized behavior. Outpatient medications, past medical history, and admission labs are provided in Table  1 . Valproate level on admission was 82 lg/mL.
Over an 8-week hospital course, the medication regimen was gradually changed to VPA solution 1250 mg every morning and 1500 mg at bedtime, haloperidol 5 mg twice daily, clonazepam 1 mg at bedtime. Valproate level was found to be 141 lg/mL (7.5-hour post-dose level at steady state; true trough calculated to be ;88 lg/mL) and ammonia was elevated at 63 lmol/L, increased from 47 and 49 lmol/L earlier in the admission. No changes in mental status were noted with elevated ammonia. Levocarnitine 990 mg was given once. Ten hours later, ammonia decreased to 44 lmol/L and 13-hour post-dose VPA level was 64 lg/mL. The patient was discharged on 
Case 3
A 53-year-old acutely manic male with bipolar I disorder and substance use disorder was transferred from an outside hospital. Outpatient medications, past medical history, and labs after transfer are reported in Table 1 .
The patient was continued on the medications from the outside hospital. During his admission at our facility, the patient was briefly transferred to the medicine service due to hypernatremia, which the medicine team attributed to lithium and stopped the medication. At time of transfer back to the psychiatric unit, the patient was initiated on VPA solution 1000 mg twice daily. Over the next 4 days, ammonia levels were found to be elevated at 59, 65, and 82 lmol/L. Once at steady state, VPA level was 104 lg/ mL. Manic symptoms persisted but no changes in mental status were noted. Despite lack of symptoms, lactulose was started for hyperammonemia and given for 3 days. Two days after lactulose was initiated, levocarnitine was also started at 1000 mg daily for 3 days then increased to twice daily. Ammonia levels decreased but remained elevated during the 2 weeks following levocarnitine initiation at 70, 58, 67, and 68 lmol/L. Levocarnitine was then increased to 1000 mg every morning and 1500 mg every evening during the second week to target hyperammonemia. After 3 weeks, ammonia levels were checked every 8 to 10 days and found to be within normal range or slightly elevated at 46, 46, 59, and 49 lmol/L. The patient was discharged on VPA and levocarnitine. Similar to our second case, it was unclear if the patient was adherent to levocarnitine as an outpatient. He was readmitted to our psychiatry unit again and found to have a VPA level of 115 lg/mL and an ammonia level of 74 lmol/L, which decreased to 30 lmol/L after levocarnitine supplementation.
Literature Review
A PubMed search was performed through June 2017 with search terms including valproate, valproic acid, hyperammonemia, altered mental status, encephalopathy, and levocarnitine. References of articles obtained from the search were also screened for inclusion. In this review, we present only relevant medical literature assessing VPA-treated patients with psychiatric disorders. To summarize results that are applicable to the patients in our case series, reports describing valproic acid use for epilepsy were not included.
Forty-four cases of VHE in the psychiatric setting were identified 1,8,10-18 along with 1 report of asymptomatic hyperammonemia with long-term VPA therapy. 9 Of these cases, 6 described the use of levocarnitine 9, [15] [16] [17] [18] and are summarized in Table 2 . Presented patients had VPA levels that ranged from 73 to 120 lg/mL and elevated ammonia levels that ranged from 96 to 377 lmol/L. Clinical presentation ranged from asymptomatic to mild lethargy to coma. Levocarnitine was given by intravenous route in 2 cases at doses of 100 mg/kg and 3 g, respectively. Authors [15] [16] [17] [18] observed a decrease in ammonia levels within 6 to 7 hours of IV administration. Levocarnitine oral supplementation doses ranged from 1500 to 2970 mg/d divided 2 to 3 times daily. Five of the 6 case reports described decreased ammonia levels and resolution of symptoms (if any) with levocarnitine use. Valproate was continued in 3 of the cases in the setting of decreased ammonia levels with levocarnitine supplementation. However, Young and Coffey 18 described a pediatric patient who had persistent ammonia elevations when VPA was continued despite levocarnitine oral supplementation up to 1500 mg/d divided twice daily.
One observational study 19 was identified that examined the effect of levocarnitine supplementation (30 mg/kg body weight daily, route not reported) in VPA-treated patients (n ¼ 22) with continuous hyperammonemia (NH 3 . 50.5 lmol/L) for at least 3 months. All patients were receiving psychiatric care (inpatient or outpatient not specified) at Kusatsu Hospital in Hiroshima, Japan and followed prospectively from September 2013 to June 2014. The authors made no comment on whether the patients experienced symptoms of encephalopathy at baseline or any point throughout the duration. They found that levocarnitine led to a significant increase in mean total carnitine levels after 3 months of supplementation. Ammonia reduction from baseline over 3 months was observed in over half (12/22) of participants. However, the mean ammonia level at 3 months was not significantly different from baseline.
Discussion
Hyperammonemia may be a relatively common adverse effect of VPA in patients with psychiatric disorders based on prospective studies. 20, 21 One study 20 found that 51% of VPA-treated patients had asymptomatic hyperammonemia compared to 21.7% of patients taking other mood stabilizers. While often asymptomatic, elevations in ammonia can progress to VHE. Risk factors associated with VHE include age less than 2 years, therapy with multiple antiepileptic drugs, developmental disability, vegan/vegetarian diets, and urea cycle disorders. 1, 7, 16 Phenytoin, phenobarbital, carbamazepine, and topiramate interact with VPA and may also precipitate VHE. 1 Prevalence of VHE in patients with hyperammonemia is unknown. In 1 retrospective study 22 of VPA-treated patients with psychiatric disorders and hyperammonemia during a 5-year period, only 20 of 793 (2.52%) patients had symptoms consistent with VHE.
Based on the literature reviewed, several case reports suggest that levocarnitine may be effective for reduction of ammonia levels in patients with psychiatric disorders on VPA therapy. In addition, the highest quality evidence available from our literature search was described in a single prospective, observational trial examining ammonia levels in VPA-treated patients after 3 months of levocarnitine supplementation. 19 In this study, levocarnitine was effective in decreasing ammonia levels in over half of the participants. While mean ammonia level at the end of the study was not significantly different from baseline, ability to detect a difference may have been limited due to the small sample size. In this observational cohort as well as the case reports described, lack of a placebo comparator makes it impossible to ascertain whether decreased ammonia levels are associated with levocarnitine supplementation rather than the result of normal physiologic changes.
In our series of 3 cases, we also described levocarnitine supplementation in the psychiatric setting for VPAinduced hyperammonemia, which resulted in reduced ammonia levels. In our first case, the patient developed encephalopathy with resolution of symptoms after VPA discontinuation. Valproate was restarted with the addition of levocarnitine to prevent VHE from reoccurring. In the other cases, levocarnitine was started as a prophylactic measure in patients who developed hyperammonemia without emergence of any clinical symptoms.
Levocarnitine is supplied as an oral preparation (1g/10 mL solution, 330 mg tablets, 500 mg tablets) and an intravenous preparation (2 g/10 mL). [23] [24] [25] Levocarnitine was dosed at a range of 1980 to 2500 mg divided twice daily in patients from our cases series, which was consistent with case reports from the literature review. The manufacturer recommended dosing approved by the Food and Drug Administration for levocarnitine oral supplementation for primary and secondary (inborn error of metabolism) carnitine deficiency is 990 mg 2 to 3 times daily for tablets and 1 g 2 to 3 times daily for solution. 23, 24 Intravenous levocarnitine is indicated for carnitine deficiency secondary to metabolic disorders and in end stage renal disease. 26 Levocarnitine was well tolerated in our patients with no adverse effects. Common adverse effects reported with levocarnitine include nausea, dose-related diarrhea, and fishy body odor. 7 Although generally well tolerated, it is important to consider clinical need for levocarnitine. Patients with VPA-induced hyperammonemia are often asymptomatic and clinical significance of ammonia reduction in these patients is difficult to determine. Nonadherence to levocarnitine and discontinuation by outpatient providers may also affect maintenance of normal ammonia levels as evidenced by elevated ammonia levels upon readmission in our patients.
Carnitine levels were not obtained in our patients. Hypocarnitinemia may be a more compelling indication for levocarnitine supplementation in cases of hyperammonemia without clear clinical symptoms. In a retrospective chart review of psychiatric patients, 38 patients were identified as having documented hypocarnitinemia and being prescribed levocarnitine (mean dose 660 mg/d, mean duration 6.4 months) with 71% of these patients prescribed VPA. After correction of carnitine levels, MiniMental State Examination scores improved in most patients (mean improvement 5.5 points, P , .0001), and normalized in 11 cases. 26 This finding was supported by another study 19 that showed improvement in the mental retardation item of the Brief Psychiatric Rating Scale after 3 months of levocarnitine supplementation in patients with VPA-induced hyperammonemia.
In addition to hypocarnitinemia, other risk factors for VHE in the psychiatric setting should be examined in future studies. Determination of risk factors may help clinicians identify patients who may benefit from levocarnitine supplementation with long-term VPA therapy to prevent VHE.
Conclusion
Although limited to case reports and an observational trial, available evidence suggests that levocarnitine may be effective for decreasing elevated ammonia levels in patients with psychiatric disorders on VPA therapy. This case series illustrates successful use of levocarnitine supplementation for reduction of ammonia levels in the setting of VPA-induced hyperammonemia. Although these 3 patients did not develop encephalopathy while on levocarnitine supplementation, clinical significance of ammonia reduction in asymptomatic patients is unclear. 
